Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.
Latest from Joseph Haas
Rocatinlimab has met primary endpoints in Phase III studies, but analysts question the Kyowa-discovered drug’s market potential due to tolerability and unspectacular efficacy.
Plus deals involving Insilico/Qilu, Insilico/Hygtia, AstraZeneca/AbelZeta, Alteogen/Tesaro, Ellipses/Innolake and more.
Deal Snapshot: Following alliances with BMS, Genentech and Pfizer, Repertoire is partnering with Lilly to discover T-cell targeted autoimmune therapies. Deal continues a busy January for Lilly’s business development.
Boehringer Ingelheim hopes TPRC6 inhibition can provide a disease-modifying therapy for focal segmental glomerulosclerosis, which has no approved therapy. The smallest dose used in its Phase II study showed the highest response rate.
Plus deals involving Alfasigma/Innovative Molecules, Genethon/AskBio, XTL/NeuroNOS, ESTEVE/TerSera, Tahoe/Alloy, Bayer/Attralus and more.
J&J will lean on its four-drug multiple myeloma franchise to drive oncology growth during the rest of the decade, but top-seller Darzalex is facing US and EU patent expiration.